CD8A and neoplasm: Taken together, these results indicate that the combinatorial immunotherapy with UPs-4T1/EPB nanovaccine and DMXAA primed a robust CD8+ T cell response in the peripheral immune organ and facilitated CD8+ TILs infiltration in 4T1/EPB tumor-bearing mice.